News | Cardiac Diagnostics | October 20, 2017

American Heart Association, Verily and AstraZeneca Launch One Brave Idea Science Innovation Center

Boston facility will provide testing ground for researchers to collaborate on “early warning system” for coronary heart disease

American Heart Association, Verily and AstraZeneca Launch One Brave Idea Science Innovation Center

October 20, 2017 — The American Heart Association, Verily and AstraZeneca announced the opening of the One Brave Idea Science Innovation Center in Boston. The Center will be home to the Cardiovascular Medicine Innovation team, led by Calum MacRae, M.D., Ph.D., chief of cardiovascular medicine at Brigham and Women’s Hospital (BWH) who, leveraging the latest technologies and scientific advances, will continue their work for One Brave Idea, the $75 million research enterprise charged with bringing an end to coronary heart disease and its consequences.

The Science Innovation Center will provide an environment where world-renowned investigators can work quickly and collaboratively to discover new ways to identify the earliest markers of heart disease and develop strategies to stop the disease before an emergency happens. At the Innovation Center, they will have access to hospitals and clinics for real-world implementation, the engineering expertise of Massachusetts Institute of Technology (MIT), the clinical device expertise of BWH’s Next Generation Phenotyping Center, and the tech and medical innovation ecosystem in Cambridge and Boston. 

The One Brave Idea team represents a wide variety of specialties, including engineering and data science, and hails from institutions including BWH, MIT and Stanford.  They are working to create a coronary heart disease “early warning system” by examining what happens 10-20 years before risk factors typically appear.

“Facilitating collaboration among scientists is a cornerstone strategy for the American Heart Association and this team of multidisciplinary scientists aims to understand the earliest stages of the disease, figure out how it develops to prevent it from ever leading to heart attack and stroke,” said Nancy Brown, chief executive officer of the American Heart Association. “Through Verily’s informatic capabilities, AstraZeneca’s proprietary data and our evolving ecosystem of patient-centered research and scientific networks, the One Brave Idea research team will translate their findings into new prevention and treatment strategies.” 

“I’m immensely proud to lead this diverse team of investigators, who are committed to exploring and identifying the potential opportunities to prevent the development of heart disease. Creating multidisciplinary research teams to attack a problem from many angles is a model that we believe will ultimately have a significant impact on cardiovascular health,” said MacRae.

For more information:

Related Content

Videos | TCT| November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
GE Healthcare and Medis Collaborate to Expand Availability of Quantitative Flow Ratio Software
News | FFR Technologies| November 10, 2017
GE Healthcare and Dutch-based cardiovascular imaging software provider Medis announced at the 2017 Transcatheter...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies| November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
VitalConnect Raises $38 Million in Series C Equity Financing
News | Wearable Sensors| November 03, 2017
November 3, 2017 — VitalConnect Inc.
Analytics 4 Life Presents Clinical Data on Machine-Learned Cardiac Imaging Technology at TCT 2017
News | Cardiac Diagnostics| November 01, 2017
Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary Artery Disease...
Abbott SJM St. Jude Confirm RX implantable cardiac monitor (ICM).

The Abbott Confirm RX implantable cardiac monitor (ICM) is smaller than a computer thumb-drive and in implanted in a simple in-office procedure just under the skin.

Technology | Implantable Cardiac Monitor (ICM)| October 23, 2017
October 23, 2017 – The U.S.
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Analytics 4 Life Raises $25 Million for AI-Backed Cardiac Imaging Technology
News | Advanced Visualization| October 20, 2017
October 20, 2017 — Digital health company Analytics 4 Life announced it has completed a $25 million Series B financin
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Role of Telomere Length in Cardiovascular Risk Assessment
Feature | Cardiac Diagnostics| October 19, 2017 | Nanette H. Bishopric, M.D., FACC, FAHA
A new area of DNA testing involving telomere length may enhance a patient’s cardiovascular disease risk stratificatio
Overlay Init